Novartis to acquire US biotech Tourmaline Bio for $1.4B, bolstering its cardiovascular pipeline with a promising anti-inflammatory drug candidate.
North Korea's latest high-thrust, solid-fuel missile engine test marks a 'significant change' in expanding its nuclear arsenal, raising concerns about its ability to strike the U.S. and allies.
Novartis to acquire US biotech Tourmaline Bio for $1.4B, bolstering its cardiovascular pipeline with a promising anti-inflammatory drug candidate.
North Korea's latest high-thrust, solid-fuel missile engine test marks a 'significant change' in expanding its nuclear arsenal, raising concerns about its ability to strike the U.S. and allies.